Compare Gerdau S.A. Common Stock (GGB) vs Hinge Health Inc. Class A Common Stock (HNGE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gerdau S.A. Common Stock vs Hinge Health Inc. Class A Common Stock — how do they compare? Gerdau S.A. Common Stock trades at $5.15 (market cap $9.66B), while Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B). The key difference: Gerdau S.A. Common Stock and Hinge Health Inc. Class A Common Stock are close in size by market cap, and Gerdau S.A. Common Stock pays a 3.48% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gerdau S.A. Common Stock for 6 Days and Hinge Health Inc. Class A Common Stock for 0 Days on average.
| GGB | HNGE | |
|---|---|---|
Market Cap | $9.66B | $8.48B |
Volume | 9,572,970 | 879,799 |
Sector | Basic Materials | Health |
52-Week High | $5.18 | $105.14 |
52-Week Low | $3.25 | $31.17 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $11.61B | $8.10B |
Dividend Yield | 3.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gerdau (GGB) trades at $5.18, up 0.78% with strong technical momentum and bullish moving average signals. The company reported mixed Q2 2026 earnings meeting expectations but missed previous quarters, while showing improved profitability with net income margin expanding to 3.23%. Recent news highlights institutional buying interest and dividend appeal, with the stock approaching its 52-week high of $5.48.
GGB presents a value opportunity with attractive valuation multiples (P/S 0.73, P/B 0.95) and strong analyst support (70% buy ratings). However, recent earnings misses and competitive pressures in Brazilian operations pose execution risks. The improving cash flow trajectory and institutional accumulation suggest potential upside if operational improvements continue.
Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.
The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gerdau S.A. Common Stock
Gerdau is a steel producer with operations across the Americas. It makes long steel, specialty steel, and other products for construction and industrial markets.
Read more on GGB →About Hinge Health Inc. Class A Common Stock
Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.
Read more on HNGE →
